Frankrig - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

sandoz - roxithromycine 150 mg - comprimé - 150 mg - pour un comprimé > roxithromycine 150 mg - antibactériens à usage systémique - classe pharmacothérapeutique : antibactériens à usage systémique - code atc : j01fa06 (j : anti-infectieux).il est utilisé pour le traitement de certaines infections bactériennes à germes sensibles (pouvant être détruits par cet antibiotique).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; macrogol 4000; magnesium stearate; lactose monohydrate; titanium dioxide; silicon dioxide; poloxamer; hypromellose - adults: roxithromycin sandoz is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms. upper respiratory tract infection: acute pharyngitis, tonsilitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin sandoz 150mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible microorganisms. acute pharyngitis. acute tonsilitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be inititiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Belgien - tysk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurogenerics afgekort "e.g." - roxithromycin - filmtablette - 150 mg - roxithromycin 150 mg - roxithromycin

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: hyprolose; povidone; propylene glycol; purified talc; sodium starch glycollate type a; hypromellose; sodium starch glycollate type b; maize starch; magnesium stearate; colloidal anhydrous silica; poloxamer; glucose; titanium dioxide - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: povidone; sodium starch glycollate type a; glucose; purified talc; hypromellose; maize starch; sodium starch glycollate type b; propylene glycol; hyprolose; poloxamer; titanium dioxide; colloidal anhydrous silica; magnesium stearate - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible microorganisms: acute pharyngitis. acute tonsillitis, impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - roxithromycin -

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ratiopharm gmbh (3087881) - roxithromycin - filmtablette - roxithromycin (23283) 300 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ratiopharm gmbh (3087881) - roxithromycin - filmtablette - roxithromycin (23283) 150 milligramm